Stock 2183 LINICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Linical Co., Ltd.

Equities

2183

JP3974530002

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-31 am EDT 		5-day change 1st Jan Change
399 JPY +2.84% Intraday chart for Linical Co., Ltd. +1.01% -24.72%
May. 15 Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025 CI
May. 15 Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 30,740 18,453 17,753 20,621 15,743 9,012 - -
Enterprise Value (EV) 1 30,408 17,396 17,359 18,740 12,241 8,899 3,935 3,327
P/E ratio 54.2 x 38.2 x 32.9 x 26.1 x 15.7 x 26.3 x 15 x 17 x
Yield 0.88% 1.71% 1.78% 1.53% 2.01% 3.81% 4.01% 4.01%
Capitalization / Revenue 2.72 x 1.69 x 1.73 x 1.78 x 1.26 x 0.72 x 0.72 x 0.73 x
EV / Revenue 2.69 x 1.59 x 1.69 x 1.62 x 0.98 x 0.72 x 0.31 x 0.27 x
EV / EBITDA 18.3 x 11.9 x 19.8 x 12.3 x 6.97 x 4.43 x 2.91 x 2.66 x
EV / FCF -31.2 x 38.6 x -316 x 12.1 x 6.92 x 9.33 x 4.85 x 3.62 x
FCF Yield -3.21% 2.59% -0.32% 8.29% 14.5% 10.7% 20.6% 27.7%
Price to Book 5.85 x 3.46 x 3.11 x 3.15 x 2.08 x 1.08 x 1.06 x 1.04 x
Nbr of stocks (in thousands) 22,587 22,587 22,586 22,586 22,586 22,586 - -
Reference price 2 1,361 817.0 786.0 913.0 697.0 399.0 399.0 399.0
Announcement Date 5/15/19 5/25/20 5/14/21 5/16/22 5/15/23 5/15/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,313 10,935 10,279 11,555 12,517 12,307 12,600 12,400
EBITDA 1 1,660 1,464 876.3 1,526 1,757 1,147 1,350 1,250
EBIT 1 1,212 1,005 453 1,086 1,257 725 900 800
Operating Margin 10.71% 9.19% 4.41% 9.4% 10.04% 5.89% 7.14% 6.45%
Earnings before Tax (EBT) 1 1,164 808 358 1,032 1,379 660 850 750
Net income 1 568 482 539 790.5 1,004 338 600 530
Net margin 5.02% 4.41% 5.24% 6.84% 8.02% 2.75% 4.76% 4.27%
EPS 2 25.09 21.38 23.91 35.00 44.47 14.98 26.60 23.50
Free Cash Flow 1 -976 451 -55 1,554 1,770 954 812 920
FCF margin -8.63% 4.12% -0.54% 13.45% 14.14% 7.75% 6.44% 7.42%
FCF Conversion (EBITDA) - 30.8% - 101.8% 100.76% 76.29% 60.15% 73.6%
FCF Conversion (Net income) - 93.57% - 196.59% 176.23% 282.25% 135.33% 173.58%
Dividend per Share 2 12.00 14.00 14.00 14.00 14.00 15.00 16.00 16.00
Announcement Date 5/15/19 5/25/20 5/14/21 5/16/22 5/15/23 5/15/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4
Net sales 1 5,389 4,981 2,738 5,522 3,091 2,941 2,868 3,052 5,921 3,327 3,270 3,082 2,982 6,064 3,184 3,148 3,062 6,210 3,255 3,135
EBITDA - - - - - - - - - - - - - - - - - - - -
EBIT 1 571 185 361.9 507.7 329 249.2 -26 400.2 373.4 367.3 516.4 112.1 309.2 421.2 220 195 295 490 260 150
Operating Margin 10.6% 3.71% 13.22% 9.19% 10.64% 8.47% -0.91% 13.12% 6.31% 11.04% 15.79% 3.64% 10.37% 6.95% 6.91% 6.19% 9.63% 7.89% 7.99% 4.78%
Earnings before Tax (EBT) 429 77 293.7 388 382 - 139 - 678 144 - 64 - 374 146 - - - - -
Net income 1 230 -13 185 252.6 272.3 265.6 76 391.9 468.8 110 426.8 3.532 175.4 178.9 74.64 130 197 328 174 97
Net margin 4.27% -0.26% 6.76% 4.57% 8.81% 9.03% 2.65% 12.84% 7.92% 3.31% 13.05% 0.11% 5.88% 2.95% 2.34% 4.13% 6.43% 5.28% 5.35% 3.09%
EPS 10.20 -0.6100 8.000 11.18 12.06 - 3.410 - 20.76 4.810 - 0.1600 - 7.920 3.310 - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - -
Announcement Date 11/14/19 11/13/20 11/12/21 11/12/21 2/14/22 5/16/22 8/12/22 11/14/22 11/14/22 2/14/23 5/15/23 8/14/23 11/14/23 11/14/23 2/14/24 - - - - -
1JPY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 332 1,057 394 1,881 3,502 3,928 5,077 5,685
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -976 451 -55 1,554 1,770 954 812 920
ROE (net income / shareholders' equity) 10.9% 9.1% 9.8% 12.9% 14.2% 4.3% 7.2% 6.2%
ROA (Net income/ Total Assets) 11.1% 6.67% 3.98% 7.63% 7.73% 4.39% 4.8% 4.2%
Assets 1 5,101 7,224 13,539 10,356 12,987 7,702 12,500 12,619
Book Value Per Share 2 232.0 236.0 253.0 290.0 336.0 365.0 375.0 383.0
Cash Flow per Share 30.90 29.40 32.70 43.20 52.60 22.70 - -
Capex 1 180 741 78 77 69 111 100 100
Capex / Sales 1.59% 6.78% 0.76% 0.67% 0.55% 0.9% 0.79% 0.81%
Announcement Date 5/15/19 5/25/20 5/14/21 5/16/22 5/15/23 5/15/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Linical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LINICAL CO., LTD. Stock Linical Co., Ltd.
-24.72% 57.32M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2183 Stock
  4. Financials Linical Co., Ltd.